# Silence Therapeutics plc: Form 20-F for the period ended Dec 31, 2023

- Company: [Silence Therapeutics plc](/companies/sln.md) (CIK 1479615)
- Form: 20-F
- Filed: 2024-03-13
- Accepted by EDGAR: Mar 13, 2024, 12:52 ET
- Period: 2023-12-31
- Accession: 0000950170-24-030519
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1479615/000095017024030519/sln-20231231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1479615/000095017024030519/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Shares outstanding | at 2023-12-31 | 118,846,966 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1479615/000095017024030519/sln-20231231.htm

Filed Mar 13, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-030519. Last ingested by Listed: Oct 24, 2026, 15:08 ET. No prices; not investment advice.